

Nelson B Watts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7525434/publications.pdf>

Version: 2024-02-01

27
papers

6,783
citations

304368

22
h-index

500791

28
g-index

30
all docs

30
docs citations

30
times ranked

4779
citing authors

#	ARTICLE	IF	CITATIONS
1	Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1479-1491.	3.1	1,397
2	A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. <i>American Journal of Medicine</i> , 2000, 109, 267-276.	0.6	1,026
3	Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 1990, 323, 73-79.	13.9	961
4	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update. <i>Endocrine Practice</i> , 2020, 26, 1-46.	1.1	493
5	American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2016—Executive Summary. <i>Endocrine Practice</i> , 2016, 22, 1111-1118.	1.1	453
6	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 157-166.	1.8	356
7	Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. <i>American Journal of Medicine</i> , 1993, 95, 557-567.	0.6	353
8	Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. <i>New England Journal of Medicine</i> , 2017, 377, 28-40.	13.9	340
9	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 44-51.	1.8	212
10	National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): What They Mean to the Bone Densitometrist and Bone Technologist. <i>Journal of Clinical Densitometry</i> , 2008, 11, 473-477.	0.5	183
11	Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis. <i>American Journal of Medicine</i> , 1997, 103, 468-476.	0.6	147
12	Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 645-653.	3.1	143
13	Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. <i>New England Journal of Medicine</i> , 2020, 382, 328-340.	13.9	138
14	Application of the 1994 WHO Classification to Populations Other Than Postmenopausal Caucasian Women: The 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2006, 9, 22-30.	0.5	116
15	Long-Term Outcomes of Elagolix in Women With Endometriosis. <i>Obstetrics and Gynecology</i> , 2018, 132, 147-160.	1.2	91
16	2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. <i>Journal of Clinical Densitometry</i> , 2013, 16, 472-481.	0.5	71
17	Postmenopausal Osteoporosis: A Clinical Review. <i>Journal of Women's Health</i> , 2018, 27, 1093-1096.	1.5	61
18	Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. <i>Obstetrics and Gynecology</i> , 2018, 132, 1252-1264.	1.2	51

#	ARTICLE	IF	CITATIONS
19	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2443-2452.	1.8	48
20	Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. <i>Obstetrics and Gynecology</i> , 2020, 135, 1313-1326.	1.2	41
21	Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2019, 30, 1187-1194.	1.3	25
22	Adverse bone effects of medications used to treat non-skeletal disorders. <i>Osteoporosis International</i> , 2017, 28, 2741-2746.	1.3	24
23	History of etidronate. <i>Bone</i> , 2020, 134, 115222.	1.4	21
24	Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life. <i>Journal of Women's Health</i> , 2021, 30, 1416-1430.	1.5	14
25	Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population. <i>JBMR Plus</i> , 2020, 4, e10401.	1.3	4
26	Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVEExtend phase 3 trial. <i>Osteoporosis International</i> , 2021, 32, 55-61.	1.3	3
27	Letter to the Editor: "Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-Analysis". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3022-e3023.	1.8	1